MA33945B1 - Procédés de fabrication d'un principe pharmaceutiquement actif - Google Patents

Procédés de fabrication d'un principe pharmaceutiquement actif

Info

Publication number
MA33945B1
MA33945B1 MA35092A MA35092A MA33945B1 MA 33945 B1 MA33945 B1 MA 33945B1 MA 35092 A MA35092 A MA 35092A MA 35092 A MA35092 A MA 35092A MA 33945 B1 MA33945 B1 MA 33945B1
Authority
MA
Morocco
Prior art keywords
methods
making effective
effective pharmaceuticals
pharmaceuticals
making
Prior art date
Application number
MA35092A
Other languages
Arabic (ar)
English (en)
Inventor
Frans Therkelsen
Michael Harold Rock
Svend Treppendahl
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MA33945B1 publication Critical patent/MA33945B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La présente invention concerne des procédés de préparation d'un principe pharmaceutiquement actif et de ses sels pharmaceutiquement acceptables.
MA35092A 2009-12-23 2010-12-20 Procédés de fabrication d'un principe pharmaceutiquement actif MA33945B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23
PCT/DK2010/050348 WO2011076212A2 (fr) 2009-12-23 2010-12-20 Procédés de fabrication d'un principe pharmaceutiquement actif

Publications (1)

Publication Number Publication Date
MA33945B1 true MA33945B1 (fr) 2013-01-02

Family

ID=43567689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35092A MA33945B1 (fr) 2009-12-23 2010-12-20 Procédés de fabrication d'un principe pharmaceutiquement actif

Country Status (37)

Country Link
US (3) US8461353B2 (fr)
EP (1) EP2516394B1 (fr)
JP (2) JP5864435B2 (fr)
KR (2) KR101796330B1 (fr)
CN (2) CN102656146B (fr)
AR (1) AR079580A1 (fr)
AU (1) AU2010335659B2 (fr)
BR (1) BR112012015749A2 (fr)
CA (1) CA2785440C (fr)
CL (1) CL2012001725A1 (fr)
CR (1) CR20120316A (fr)
CY (1) CY1118032T1 (fr)
DK (1) DK2516394T3 (fr)
DO (1) DOP2012000170A (fr)
EA (1) EA021440B1 (fr)
ES (1) ES2575666T3 (fr)
GE (1) GEP20146078B (fr)
HR (1) HRP20160518T1 (fr)
HU (1) HUE028806T2 (fr)
IL (2) IL220329A (fr)
MA (1) MA33945B1 (fr)
ME (1) ME02401B (fr)
MX (1) MX2012007078A (fr)
MY (1) MY159251A (fr)
NZ (2) NZ625798A (fr)
PH (1) PH12012501258A1 (fr)
PL (1) PL2516394T3 (fr)
PT (1) PT2516394E (fr)
RS (1) RS54820B1 (fr)
SG (1) SG181910A1 (fr)
SI (1) SI2516394T1 (fr)
SM (1) SMT201600166B (fr)
TN (1) TN2012000279A1 (fr)
TW (1) TW201139370A (fr)
UA (1) UA111584C2 (fr)
WO (1) WO2011076212A2 (fr)
ZA (1) ZA201305936B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
US20160168089A1 (en) 2014-12-12 2016-06-16 H. Lundbeck A/S Process for the manufacture of idalopirdine
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
WO2017067670A1 (fr) 2015-10-23 2017-04-27 Pharmathen S.A. Nouveau procédé de préparation de tryptamines et de leurs dérivés
WO2017174691A1 (fr) 2016-04-08 2017-10-12 H. Lundbeck A/S Procédé de fabrication d'idalopirdine par hydrogénation d'une imine
EP3333154A1 (fr) 2016-12-07 2018-06-13 Sandoz Ag Forme cristalline d'un antagoniste sélectif du récepteur 5-ht6
PL3902779T3 (pl) 2018-12-27 2023-05-15 F. Hoffmann-La Roche Ag Sposób wytwarzania egzo-n-(3-azabicyklo[3.2.1]oktan- 8-ylo)-karbaminianu tert-butylu

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) * 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
BR9408460A (pt) 1993-12-28 1997-08-05 Rhone Poulenc Chimie Processo de hidrogenação catalítica de nitrilas em aminas com o auxílio de um catalisador do tipo níquel de raney
KR100369271B1 (ko) 1993-12-28 2003-08-25 로디아 쉬미 니트릴을아민으로수소화하기위한촉매의제조방법및이수소화촉매의용도
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
KR20000069831A (ko) 1997-10-31 2000-11-25 요트.게.아. 롤페즈 구성 신호에 대한 잡음 추가를 통한 엘피씨 원칙에 따라 인코딩된 음성의 오디오 표현을 위한 방법 및 장치
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
DK1859798T3 (en) * 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
CA2633243C (fr) * 2005-12-15 2014-05-27 Exelixis, Inc. Derives d'azepinoindole en tant qu'agents pharmaceutiques
EP2002834A1 (fr) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryle/hétarylamides en tant que modulateurs du récepteur EP2
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
JP2012503654A (ja) * 2008-09-26 2012-02-09 ワイス・エルエルシー １，２，３，６−テトラヒドロアゼピノ［４，５−ｂ］インドール−５−カルボキシレート核内受容体阻害剤
CN101531624A (zh) * 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
EA201290552A1 (ru) 2012-12-28
HUE028806T2 (en) 2017-01-30
JP5864435B2 (ja) 2016-02-17
IL220329A (en) 2016-03-31
CN102656146B (zh) 2014-12-17
KR101796330B1 (ko) 2017-11-09
NZ600639A (en) 2014-07-25
PT2516394E (pt) 2016-06-07
HK1196352A1 (en) 2014-12-12
IL231141A0 (en) 2014-03-31
HK1174921A1 (en) 2013-06-21
CN102656146A (zh) 2012-09-05
JP2013515683A (ja) 2013-05-09
US8461353B2 (en) 2013-06-11
TN2012000279A1 (en) 2013-12-12
US9382205B2 (en) 2016-07-05
US8901318B2 (en) 2014-12-02
CR20120316A (es) 2012-08-16
AU2010335659B2 (en) 2015-05-21
CL2012001725A1 (es) 2012-11-30
AR079580A1 (es) 2012-02-01
PL2516394T3 (pl) 2016-09-30
KR101873182B1 (ko) 2018-06-29
WO2011076212A3 (fr) 2011-08-11
CY1118032T1 (el) 2017-05-17
SMT201600166B (it) 2016-07-01
UA111584C2 (uk) 2016-05-25
SI2516394T1 (sl) 2016-07-29
BR112012015749A2 (pt) 2015-09-15
AU2010335659A1 (en) 2012-07-05
CN103694161B (zh) 2015-09-09
NZ625798A (en) 2014-10-31
DK2516394T3 (en) 2016-06-13
IL231141A (en) 2016-03-31
ZA201305936B (en) 2015-09-30
DOP2012000170A (es) 2012-08-31
MX2012007078A (es) 2012-07-20
MY159251A (en) 2016-12-30
CA2785440C (fr) 2018-05-01
CN103694161A (zh) 2014-04-02
HRP20160518T1 (hr) 2016-06-03
ME02401B (fr) 2016-09-20
ES2575666T3 (es) 2016-06-30
US20130245281A1 (en) 2013-09-19
CA2785440A1 (fr) 2011-06-30
IL220329A0 (en) 2012-08-30
TW201139370A (en) 2011-11-16
EP2516394A2 (fr) 2012-10-31
SG181910A1 (en) 2012-08-30
JP2016117734A (ja) 2016-06-30
GEP20146078B (en) 2014-04-10
RS54820B1 (sr) 2016-10-31
EP2516394B1 (fr) 2016-03-16
EA021440B1 (ru) 2015-06-30
WO2011076212A2 (fr) 2011-06-30
PH12012501258A1 (en) 2013-02-04
US20150080584A1 (en) 2015-03-19
KR20170125417A (ko) 2017-11-14
US20110152539A1 (en) 2011-06-23
JP6195605B2 (ja) 2017-09-13
KR20120112480A (ko) 2012-10-11

Similar Documents

Publication Publication Date Title
MA33945B1 (fr) Procédés de fabrication d'un principe pharmaceutiquement actif
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
UA105229C2 (uk) Фармацевтичний склад
MA38050A1 (fr) Inhibiteurs de gdf-8
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
EA200970296A1 (ru) Содержащие диариловый эфир соединения мочевины
EA201390723A1 (ru) Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep
EA201200390A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
PE20121337A1 (es) Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
EA200800147A1 (ru) Способ получения олмесартан медоксомила
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
IN2012DN02502A (fr)
MA35188B1 (fr) Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
MA32290B1 (fr) Nouvelle classe de spiro pipéridines pour le traitement de maladies neurodégénératives
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX2010010455A (es) Formas solidas de un compuesto fosfoindol anti-vih.
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
MY179041A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound